Drug intelligence / Profile preview

ESO-TX101

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

ESO-TX101 is an investigational in vivo cell therapy developed by EsoBiotec for the treatment of solid tumors. It is designed as a T cell therapy, though specific mechanistic and molecular details about its construct, target antigen(s), or vector platform have not been publicly disclosed. The drug is distinct from ESO-T01 (which targets BCMA in multiple myeloma) and represents a separate candidate within EsoBiotec’s pipeline focused on solid tumor indications[2][3]. As of late 2024, ESO-TX101 was reported to be in preclinical development for solid tumors[2][3].

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on ESO-TX101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESO-TX101.

Explore the full profile